Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
| ▸ | DHFR | P00374 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | RHEB | Q15382 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL830551 | 0.87 | MAPT (0.52) | TP53MAPTKDM4EAURKASRC | |
| SCHEMBL829690 | 0.87 | KDM1A (0.59) | TP53MAPTKDM4EAURKASRC | |
| SCHEMBL830704 | 0.87 | HTT (0.51) | TP53MAPTKDM4EAURKASRC | |
| SCHEMBL829774 | 0.87 | MEN1 (0.49) | TP53MAPTKDM4EAURKASRC | |
| SCHEMBL829981 | 0.83 | AURKA (0.48) | TP53MAPTKDM4EAURKAGSK3B | |
| SCHEMBL829447 | 0.83 | DHFR (0.47) | TP53MAPTKDM4EDHFRKDM1A | |
| SCHEMBL828917 | 0.83 | TP53 (0.49) | TP53MAPTKDM4EAURKASRC | |
| SCHEMBL10629041 | 0.72 | LTB4R (0.50) | MAPTKDM4EAURKAIGF1RHPGD | |
| SCHEMBL830502 | 0.72 | MAOB (0.47) | MAPTMEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL30555415 | 0.71 | TP53 (0.56) | TP53MAPTKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143276-B2 | 4-thio substituted quinoline and naphthyridine compounds | XTL BIOPHARMACEUTICALS LTD. (IL) | 2012-03-27 | — | — | US | disclosed |
| US-8143276-B2 | 4-thio substituted quinoline and naphthyridine compounds | XTL BIOPHARMACEUTICALS LTD. (IL) | 2012-03-27 | — | — | US | disclosed |
| US-8143276-B2 | 4-thio substituted quinoline and naphthyridine compounds | XTL BIOPHARMACEUTICALS LTD. (IL) | 2012-03-27 | — | — | US | disclosed |
| EP-2061466-A2 | 4-THIO SUBSTITUTED QUINOLINE AND NAPHTHYRIDINE COMPOUNDS | Xtl Biopharmaceuticals Ltd. (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20090054477-A1 | 4-thio substituted quinoline and naphthyridine compounds | PRESIDIO PHARMACEUTICALS, INC. | 2009-02-26 | — | — | US | disclosed |
| US-20090054477-A1 | 4-thio substituted quinoline and naphthyridine compounds | PRESIDIO PHARMACEUTICALS, INC. | 2009-02-26 | — | — | US | disclosed |
| US-20090054477-A1 | 4-thio substituted quinoline and naphthyridine compounds | PRESIDIO PHARMACEUTICALS, INC. | 2009-02-26 | — | — | US | disclosed |
| WO-2008024423-A2 | 4-THIO SUBSTITUTED QUINOLINE AND NAPHTHYRIDINE COMPOUNDS | XTL BIOPHARMACEUTICALS LTD. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024423-A2 | 4-THIO SUBSTITUTED QUINOLINE AND NAPHTHYRIDINE COMPOUNDS | XTL BIOPHARMACEUTICALS LTD. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054477-A1 | 4-thio substituted quinoline and naphthyridine compounds | GTF3C4, HNF4A, TENT4A | TP53 335/4885MAPT 2002/4885KDM4E 1265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.